Cytokine-primed umbilical cord mesenchymal stem cells enhanced therapeutic effects of extracellular vesicles on osteoarthritic chondrocytes.

Autor:	Nguyen TH; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam., Dao HH; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam.; Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam., Duong CM; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam.; Department of Biology, Clark University, Worcester, MA, United States., Nguyen XH; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam.; College of Health Sciences, VinUniversity, Hanoi, Vietnam., Hoang DH; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam., Do XH; Department of Practical and Experimental Surgery, Vietnam Military Medical University, Hanoi, Vietnam., Truong TQ; Hanoi Medical University, Hanoi Medical University Hospital, Hanoi, Vietnam., Nguyen TD; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam., Nguyen LT; College of Health Sciences, VinUniversity, Hanoi, Vietnam.; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam., Than UTT; Center of Applied Sciences, Regenerative Medicine and Advance Technologies, Vinmec Healthcare System, Hanoi, Vietnam.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Oct 27; Vol. 13, pp. 1041592. Date of Electronic Publication: 2022 Oct 27 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.1041592
Abstrakt:	In recent years, extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) have emerged as a potential cell-free therapy against osteoarthritis (OA). Thus, we investigated the therapeutic effects of EVs released by cytokine-primed umbilical cord-derived MSCs (UCMSCs) on osteoarthritic chondrocyte physiology. Priming UCMSCs individually with transforming growth factor beta (TGFβ), interferon alpha (IFNα), or tumor necrosis factor alpha (TNFα) significantly reduced the sorting of miR-181b-3p but not miR-320a-3p; two negative regulators of chondrocyte regeneration, into EVs. However, the EV treatment did not show any significant effect on chondrocyte proliferation. Meanwhile, EVs from both non-priming and cytokine-primed UCMSCs induced migration at later time points of measurement. Moreover, TGFβ-primed UCMSCs secreted EVs that could upregulate the expression of chondrogenesis markers ( COL2 and ACAN ) and downregulate fibrotic markers ( COL1 and RUNX2 ) in chondrocytes. Hence, priming UCMSCs with cytokines can deliver selective therapeutic effects of EV treatment in OA and chondrocyte-related disorders. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Nguyen, Dao, Duong, Nguyen, Hoang, Do, Truong, Nguyen, Nguyen and Than.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu